The emergence of dual-action receptor agonists in the management of type 2 diabetes and obesity has sparked considerable interest, particularly regarding retatrutide and tirzepatide. While both medications target both https://aoifegaxt737630.smblogsites.com/38933147/retatrutide-vs-tirzepatide-a-comparative-analysis